Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michelle Arkin
AddedMar 31, 2024
UpdatedMay 31, 2026
Michelle Arkin

Michelle Arkin

Co-Founder, Elgia Therapeutics

Crunchbase

Michelle Arkin's Career

Elgia Therapeutics
Elgia Therapeutics

San Diego, CA, US

Co-Founder
Ambagon Therapeutics
Ambagon Therapeutics

San Francisco, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michelle Arkin's Career

Elgia Therapeutics
Elgia Therapeutics
Seed$2.3M72019San Diego, CA, US
Co-Founder

Leadership at Elgia Therapeutics

Adam RensloAdam RensloCo-Founder
Michael KarinMichael KarinCo-Founder
Alan SaltielAlan SaltielCo-Founder
Ariel FeldsteinAriel FeldsteinCo-Founder

Similar to Elgia Therapeutics

Halia TherapeuticsHalia TherapeuticsSalt Lake City, UT, USTherapeuticsest. 2017Halia TherapeuticsSalt Lake City, UT, US · est. 2017

Halia Therapeutics: Preclinical biopharma firm innovating therapies for inflammatory and neurological disorders.

Series C · $47.2M11
Exalys TherapeuticsExalys TherapeuticsSan Diego, CA, USDrugs, Therapeuticsest. 2018Exalys TherapeuticsSan Diego, CA, US · est. 2018

Exalys Therapeutics develops novel anti-inflammatory drugs, targeting diseases with limited treatments.

Series A · $15M32
Eolo PharmaEolo PharmaWilmington, DE, USPharmaceuticalsest. 2017Eolo PharmaWilmington, DE, US · est. 2017

Eolo Pharma: Developing targeted drugs for inflammation-related diseases.

Seed · $4.5M5
Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
Ambagon Therapeutics
Ambagon Therapeutics
Series D$148M572020San Francisco, CA, US
Co-Founder

Leadership at Ambagon Therapeutics

Scott ClarkeScott ClarkeCEO
Peter DudekPeter DudekBoard Member
Lucas BrunsveldLucas BrunsveldCo-Founder
Christian OttmannChristian OttmannCo-Founder

Similar to Ambagon Therapeutics

Innovo TherapeuticsInnovo TherapeuticsSan Diego, CA, USAnti-Cancer Drugsest. 2021Innovo TherapeuticsSan Diego, CA, US · est. 2021

San Diego-based Innovo Therapeutics develops anti-cancer drugs targeting protein breakdown.

Seed · $200M11
Nexo TherapeuticsNexo TherapeuticsLittleton, CO, USOncology Drugsest. 2022Nexo TherapeuticsLittleton, CO, US · est. 2022

Nexo Therapeutics: Innovating small molecule oncology for effective cancer treatments.

Series A · $60M30
Ensem TherapeuticsEnsem TherapeuticsMedford, MA, USDrug Discoveryest. 2021Ensem TherapeuticsMedford, MA, US · est. 2021

ENSEM Therapeutics: A biotech firm specializing in drug discovery and development for complex oncology targets.

Series A · $77M33
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18

Michelle Arkin's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Michelle Arkin

Hsiou-Chi LiouHsiou-Chi LiouCo-Founder · ImmuneTargetMichael GerstleMichael GerstleCo-Founder · Stadius